Consensus recommendation on Comprehensive Geriatric Assessment for elderly cancer patients from Peking Union Medical College Hospital

doi:10.16352/j.issn.1001-6325.2025.09.1122

Abstract

Abstract: In the context of an aging society, the number of elderly cancer patients is constantly increasing, and geriatric oncology has garnered significant attention in recent years. Given the heterogeneity in the health status of older patients, it has become increasingly important to provide individualized diagnosis, treatment, follow-up, and care. Thus, it must be emphasized the Comprehensive Geriatric Assessment (CGA) for elderly patients, which encompasses their physical function, nutritional status, cognitive function, emotional state, comorbidities, polypharmacy, social situation, and treatment preferences. This article provides consensus recommendations on CGA tools for elderly patients prior to anticancer treatment, offering valuable references and insights for clinical practice in China.

Key words: Comprehensive Geriatric Assessment (CGA), cancer, frailty

CLC Number:

R73
R592

WANG Qiumei, LI Xiaoyuan, KANG Lin, SUN Xiaohong, LI Hailong, DUAN Yanping, LIU Ying, GUAN Mei, ZHAO Lin. Consensus recommendation on Comprehensive Geriatric Assessment for elderly cancer patients from Peking Union Medical College Hospital[J]. Basic & Clinical Medicine, 2025, 45(9): 1122-1131.

References 38

[1]	Han BF,Zheng RS,Zeng HM,et al.Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent,2024, 4:47-53.doi:10.1016/j.jncc.2024.01.006.eCollection 2024 Mar.
[2]	陈旭娇,严静,王建业,等.老年综合评估技术应用中国专家共识[J].中华老年医学杂志,2017, 36:471-477.
[3]	Corre R, Greillier L, Le Caër H, et al. Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA GFPC-GECP 08-02 study[J]. J Clin Oncol, 2016, 34: 1476-1483. doi:10.1200/JCO.2015.63.5839.
[4]	Hamaker ME, Seynaeve C, Wymenga AN, et al. Baseline comprehensive geriatric assessment is associated with toxicity and survival in elderly metastatic breast cancer patients receiving single-agent chemotherapy: results from the OMEGA study of the Dutch breast cancer trialists′ group[J]. Breast, 2014, 23: 81-87. doi:10.1016/j.breast.2013.11.004.
[5]	Anwar MR,Yeretzian ST, Ayala AP,et al.Effectiveness of geriatric assessment and management in older cancer patients: a systematic review and meta-analysis[J].J Natl Cancer Inst,2023,115:1483-1496. doi:10.1093/jnci/djad200.
[6]	Cesari M,Araujo DC, Amuthavalli T,et al. Evidence for the domains supporting the construct of intrinsic capacity[J].J Gerontol A Biol Sci Med Sci, 2018,73:1653-1660. doi:10.1093/gerona/gly011.
[7]	Veronese N, Custodero C, Cella A,et al.Prevalence of multidimensional frailty and pre-frailty in older people in different settings[J].Ageing Res Rev,2021,72:101498.doi:10.1016/j.arr.2021.101498.Epub 2021 Oct 23.
[8]	Ditzel HM, Giger AW, Lund CM, et al. Association between Geriatric 8 frailty and health-related quality of life in older patients with cancer (PROGNOSIS-G8): a Danish single-centre, prospective cohort study[J]. Lancet Healthy Longev, 2024,5:100612. doi:10.1016/S2666-7568(24)00118-1. Epub 2024 Aug 29.
[9]	Handforth C, Clegg A, Young C, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review[J]. Ann Oncol,2015,26:1091-1101. doi:10.1093/annonc/mdu540.
[10]	Ethun CG, Bilen MA, Jani AB,et al.Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology[J]. CA Cancer J Clin, 2017,67:362-377. doi:10.3322/caac.21406.
[11]	Jespersen E, Winther SB, Minet LR,et al. Shorter overall survival in older patients with gastrointestinal cancer receiving palliative chemotherapy-a prospective, clinical study[J]. J Geriatr Oncol, 2021,12:578-584. doi:10.1016/j.jgo.2020.10.007.
[12]	Narasimhulu DM, McGree ME, Weaver AL, et al. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer[J]. Gynecol Oncol, 2020,158:646-652. doi:10.1016/j.ygyno.2020.05.04612.
[13]	Ribeiro AR, Howlett SE, Fernandes A. Frailty-A promising concept to evaluate disease vulnerability[J]. Mech Ageing Dev, 2020,187:111217. doi:10.1016/j.mad.2020.111217.
[14]	Shaw JF, Budiansky D, Sharif F, et al. The association of frailty with outcomes after cancer surgery: a systematic review and metaanalysis[J]. Ann Surg Oncol, 2022,29:4690-4704. doi:10.1245/s10434-021-11321-2.
[15]	International Society of Geriatrie Oncology (SIOG). Comprehensive geriatric assessment. Available from: https://siog.org/resources/resources-siog/comprehensive-geriatric-assessment/. Accessed November 6, 2022.
[16]	Wildiers H, Heeren P, Puts M, et al. International society of geriatric oncology consensus on geriatric assessment in older patients with cancer[J]. J Clin Oncol, 2014,32:2595-2603. doi:10.1200/JCO.2013.54.8347.
[17]	Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology[J]. J Clin Oncol, 2018,36:2326-2347. doi:10.1200/JCO.2018.78.8687.
[18]	Goede V.Frailty and cancer: current perspectives on assessment and monitoring[J].Clin Interv Aging, 2023,18:505-521. doi:10.2147/CIA.S365494. eCollection 2023.
[19]	Garcia MV, Agar MR, Soo WK, et al. Screening tools for identifying older adults with cancer who may benefit from a geriatric assessment: a systematic review[J]. JAMA Oncol, 2021,7:616-627. doi:10.1001/jamaoncol.2020.6736.
[20]	Almatrafi A, Gabe R, Beeken RJ,et al.Impact of frailty and comorbidity on initial response to lung cancer screening invitation and low-dose CT screening uptake: Findings from the Yorkshire Lung Screening Trial[J].J Med Screen, 2025:9691413251315087. doi:10.1177/09691413251315087. Online ahead of print.
[21]	Hinojo C, Cantos B, Antolin S,et al.Identification and management of medical comorbidities in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: literature review and recommendations from experts in spain opinion[J].Clin Breast Cancer, 2024:S1526-8209(24)00367-7. doi:10.1016/j.clbc.2024.12.016. Online ahead of print.
[22]	McDonagh J, Lindley RI, Byth K,et al. Frailty in older adults admitted to hospital: outcomes from the Western Sydney Clinical Frailty Registry[J].BMC Geriatr, 2025,25:78. doi:10.1186/s12877-025-05715-0.
[23]	Cai PP, Gu LL,Wang X,et al.A single-center prospective cohort study assessing preoperative gait speed assessment as a prognostic tool for morbidity and mortality in frail elderly patients undergoing abdominal surgery[J].Braz J Med Biol Res, 2025,58:e14103. doi:10.1590/1414-431X2024e14103. eCollection 2025.
[24]	Tariq A, Alireza S,Zadeh M,et,al.Relationship between multiple morbidities and performance on the Timed Up and Go test in elderly patients: a cross-sectional study[J].BMJ Open,2025,15:e088950. doi:10.1136/bmjopen-2024-088950.
[25]	Schmidt AM,Kristensen HN,Melgaard D,et al. Development of a screening intervention for dysphagia in hospitalised geriatric patients.[J]. Dysphagia, 2025,30. doi:10.1007/s00455-025-10803-9. Online ahead of print.
[26]	Yuan GY, Ye GX, Hu JG,et al.Nomogram to screen older adult patients attending the radiology department for sarcopenia[J].BMC Geriatr, 2025,25:69. doi:10.1186/s12877-025-05730-1.
[27]	Chen LK, Woo J, Assantachai P, et al. Asian Working Group for Sarcopenia: 2019 consensus updated on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020,21:300-307.e2. doi:10.1016/j.jamda.2019.12.012.
[28]	Bruijnen CP,van Harten-Krouwel DG,Koldenhof JJ,et al. Predictive value of each geriatric assessment domain for older patients with cancer: a systematic review[J]. J Geriatr Oncol, 2019,10:859-873. doi:10.1016/j.jgo.2019.02.010.
[29]	Stypulkowski K, Rodrigues J, Cieri F,et al.Comparison of the beck anxiety inventory and the geriatric anxiety scale in an older adult neurology clinic sample[J].Arch Clin Neuropsychol, 2025,4:acaf006. doi:10.1093/arclin/acaf006. Online ahead of print.
[30]	Park YS,Yoo K,KimHJ,et al.Association between sarcopenia components and depressed mood varies by sex among community-dwelling older adults from the Korean Frailty and Aging Cohort Study[J].Sci Rep,2025,15:3987.doi:10.1038/s41598-025-88437-y.
[31]	Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer[J]. J Clin Oncol, 2008, 26:2925-2926.
[32]	Mohamed MR, Rich DQ, Seplaki C, et al. Primary treatment modification and treatment tolerability among older chemotherapy recipients with advanced cancer[J].JAMA Netw Open,2024,7:e2356106.doi:10.1001/jamanetworkopen.2023.56106.
[33]	Tucci A, Ferrari S, Bottelli C et al. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy[J].Cancer, 2009,115:4547-4553. doi:10.1002/cncr.24490.
[34]	Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study[J]. J Clin Oncol, 2011,29:3457-3463. doi:10.1200/JCO.2011.34.7625.
[35]	Hurria A, Mohile S, Gajra A, et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer[J]. J Clin Oncol,2016,34:2366-2371. doi:10.1200/JCO.2015.65.4327.
[36]	Extermann M, Boler I, Reich RR, et al. Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score[J]. Cancer, 2012,118:3377-3386. doi:10.1002/cncr.26646.
[37]	Ortland I, Ott MM, Kowar M, et al. Comparing the performance of the CARG and the CRASH score for predicting toxicity in older patients with cancer[J]. J Geriatr Oncol, 2020,11:997-1005. doi:10.1016/j.jgo.2019.12.016.
[38]	Pang A, Low JL, Ng A, et al. Use of the cancer and aging research group predictive model for chemotherapy-related toxic effects in a multiethnic, older adult Asian population[J]. JAMA Netw Open, 2022,5:e2237196. doi:10.1001/jamanetworkopen.2022.37196.